|Day Low/High||5.01 / 5.63|
|52 Wk Low/High||4.01 / 14.81|
Hemispherx's Experimental Biotherapeutics May Escape Mutational Impediments
Hemispherx Reports Ampligen(R) Improves Function of NK Cells Obtained From CFS Patients
Positive Effects Reported in a Melanoma Model
Independent Demonstration of Anti-Ebola Function of Hemispherx's Biotherapeutic
European University Report Establishes That VP35 Binding by Ampligen(R) May Restore Ability to Activate Effective Immune Response and Thereby Survive Infection
U.S. Governmental Collaboration Indicates That Ampligen(R) and Alferon(R) Both Exhibit In Vitro Antiviral Activity Against the Ebola Virus
... Initial Ebola Studies of Alferon(R) and Ampligen(R) at USAMRIID Show Protective Activity of Both Compounds at Low Concentrations
Biotech columnist Adam Feuerstein answers readers' questions about health care.
Ebola VP35-Induced Sequestration of a Critical Antiviral/Immune Activator is Responsible for High Mortality: A New Drug Target
All Claims by Cato Capital Dismissed by Federal Judge; Company Seeks One Million Dollar Award for Fees and Costs Against Losing Party
The Ebola outbreak has put the spotlight on Chimerix as well as other biotech companies with potential vaccines and even those stocks with marginal relation to the virus.
Dr. Mitchell Will Chair Session With Prominent Scientist From the Centers for Disease Control and Prevention
Ebola lands in Texas, so expect some crazy volatility Wednesday in biotech and drug stocks.
Hemispherx's Two Experimental Therapeutics May Provide Benefit Despite Recently Discovered Ebola Viral Mutations
WHO Reports Global Flu Reaches 5 Year High in Southern Hemisphere
Antibodies Against Flu Strains With Pandemic Potential Observed
Twitter abuzz with speculation that Tekmira's experimental Ebola therapy is being used to treat patient.
The Ebola outbreak in West Africa is a public health emergency which has also captured the attention of U.S. investors (perhaps I should say traders.)
WHO Declares "A Clinical Emergency All Over the World."
Ebola Studies to be Conducted at USAMRIID's Laboratories at Ft. Detrick, Maryland
Receives New U.S. Composition of Matter Patent Covering Ampligen(R) Formulations
By publicizing its outreach to the U.S. government about an experimental ebola treatment, Sarepta comes off looking like just another opportunistic, self-promoting drug developer.
New Publication Compares Achievable Concentrations in Humans of Various Interferons and Other Potential Drug Treatments
New Report Compares Achievable Concentrations of Various Candidate Treatments in Humans; CDC Issues New Guidelines for Protections
Builds on Recently Issued Patent Estates of Both Companies and Basic Research / Clinical Advancement in Cancer Control
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.